PTPN11 and neuroblastoma: In summary, our results suggest that SHP2 combination regimens are a promising therapeutic strategy to further investigate as a possible regimen for patients with neuroblastoma and other solid tumors with multiple genetic aberrations in the RAS/MAPK/SHP2 pathways, to provide opportunities to enhance drug sensitivity and potentially impact resistance to single agents.